Form 8-K - Current report:
SEC Accession No. 0001104659-26-047735
Filing Date
2026-04-23
Accepted
2026-04-23 16:30:11
Documents
11
Period of Report
2026-04-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K crvs-20260422x8k.htm   iXBRL 8-K 36154
  Complete submission text file 0001104659-26-047735.txt   144562

Data Files

Seq Description Document Type Size
2 EX-101.SCH crvs-20260422.xsd EX-101.SCH 2691
3 EX-101.LAB crvs-20260422_lab.xml EX-101.LAB 15262
4 EX-101.PRE crvs-20260422_pre.xml EX-101.PRE 9931
14 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20260422x8k_htm.xml XML 4704
Mailing Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 26889089
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)